Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials

被引：0
|
作者：
Amy McMichael
Seemal R. Desai
Aamir Qureshi
Shipra Rastogi
Andrew F. Alexis
机构：
[1] Wake Forest Baptist Medical Center,Department of Dermatology
[2] Medical Center Boulevard,undefined
[3] Innovative Dermatology,undefined
[4] University of Texas Southwestern Medical Center,undefined
[5] Ortho Dermatologics,undefined
[6] Mount Sinai St. Luke’s and Mount Sinai West,undefined
来源：
American Journal of Clinical Dermatology | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 276
页数：9
相关论文
共 50 条
  • [21] Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis
    Umezawa, Y.
    Nakagawa, H.
    Niiro, H.
    Ootaki, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (11) : 1957 - 1960
  • [22] Efficacy and safety of secukinumab by age group in patients with moderate-to-severe plaque psoriasis: Pooled analysis of 4 phase III trials
    Draelos, Zoe
    Kempers, Steven
    Helfrich, Yolanda
    Meng, Xiangyi
    Fox, Todd
    Nyirady, Judit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB247 - AB247
  • [23] Efficacy and Safety of Ixekizumab in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis
    Paller, Amy
    Seyger, Marieke
    Alejandro Magarinos, Gabriel
    Bagel, Jerry
    Keller, Stuart
    Capriles, Claudia Rodriguez
    Gallo, Gaia
    Edson-Heredia, Emily
    Li, Lingnan
    Xu, Wen
    Papp, Kim
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 17 - 17
  • [24] Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: Results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12
    Papp, Kim
    Reich, Kristian
    Leonardi, Craig
    Paul, Carle
    Blauvelt, Andrew
    Baran, Wojciech
    Bolduc, Chantal
    Toth, Darryl
    Langley, Richard
    Cather, Jennifer
    Gottlieb, Alice
    Thaci, Diamant
    Milmont, Cassandra
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB233 - AB233
  • [25] Efficacy and safety of guselkumab for the treatment of patients with moderate-to-severe plaque psoriasis: A meta-analysis of randomized clinical trials
    Tao, Xing-Bao
    Huang, Yin-Qiu
    Zhou, Yi-Hong
    Zhang, Lv-Lang
    Chen, Yao-Kai
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (02) : 433 - 440
  • [26] Integrated safety of ixekizumab in patients with moderate-to-severe psoriasis: results from a pooled analysis of 7 clinical trials
    Strober, B.
    Papp, K.
    Leonardi, C.
    Bissonnette, R.
    Ferris, L.
    Mrowietz, U.
    Paul, C.
    Lebwohl, M.
    Braun, D.
    Reich, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S170 - S170
  • [27] Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and-3 studies
    Zachariae, Claus
    Mrowietz, Ulrich
    Andersen, Jens Strodl
    Puig, Lluis
    EUROPEAN JOURNAL OF DERMATOLOGY, 2022, 32 (04) : 530 - 535
  • [28] Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28
    Papp, K. A.
    Reich, K.
    Blauvelt, A.
    Kimball, A. B.
    Gooderham, M.
    Tyring, S. K.
    Sinclair, R.
    Thaci, D.
    Li, Q.
    Cichanowitz, N.
    Green, S.
    La Rosa, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (06) : 1098 - 1106
  • [29] Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
    Elewski, Boni
    Han, George
    Rozzo, Stephen J.
    Gogineni, Ranga
    Schenkel, Brad
    Guenthner, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB57 - AB57
  • [30] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Kruger, J. G.
    Tsai, T.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H.
    Paul, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
12345